4basebio
4BB · AIM · Health Care · mcap £85m · 562.5p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 28 Sep 26 | Results | Half-year Results
Cambridge, UK, 28 September 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing for next-generation genomic medicines and advanced therapies, announces its unaudited half-year results for the six |
+0.0% |
| 28 Sep 26 | 4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company's Phase I Cell Therapy Program
4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company’s Phase I Cell Therapy Program |
+0.0% | |
| 07 Sep 26 | 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine
4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine |
+1.1% | |
| 26 Aug 26 | 4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing
Commercial collaboration combines 4basebio’s synthetic DNA technology with Genezen’s viral vector development and manufacturing expertise to support gene therapy programs from early development through clinical and comme |
+1.1% | |
| 26 Aug 26 | 4basebio Enters into Strategic Collaboration and Marketing Agreement with Genezen to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing
4basebio Enters into Strategic Collaboration and Marketing Agreement with Genezen to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing |
+1.1% | |
| 22 Jul 26 | Director dealing | Grant of Options & Director/PDMR Dealing | |
| 08 Jul 26 | Director Appointment
4basebio PLC (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, is pleased to announce the apppointent of Mr. |
+0.0% | |
| 30 Jun 26 | Routine | Result of AGM & Issue of Options | |
| 16 Jun 26 | Notice of Investor Presentation
– 4basebio PLC (AIM: 4BB),a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces that it will provide a live investor presentation on 29 June 2026. |
+0.0% | |
| 15 Jun 26 | 4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board
, brings deep expertise to accelerate synthetic DNA and mRNA manufacturing |
+0.0% | |
| 05 Jun 26 | Routine | Notice of AGM | |
| 22 May 26 | Director dealing | Director/PDMR Shareholding | |
| 20 May 26 | Final Results and Notice of AGM
a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025. |
+7.9% | |
| 20 May 26 | 4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial
Oncology focused biotech to utilise 4basebio’s opDNA® technology to support Phase II clinical trial of immunotherapy candidate |
+7.9% | |
| 14 May 26 | Board change | Appointment of Chief Financial Officer and Board Changes
Appointment of Chief Financial Officer and Board Changes |
+0.0% |
| 11 May 26 | 4basebio Launches Enzymatic ssDNA Platform
Overcomes critical manufacturing and performance bottlenecks associated with traditional chemical synthesis, providing faster and more reliable ssDNA manufacturing to aid commercial scale up |
+0.0% | |
| 31 Mar 26 | Lease of Manufacturing Facility
4basebio announces major expansion to support the growing demand of RUO and HQ synthetic DNA with lease of an innovation hub and manufacturing facility in Cambridge, UK |
−1.0% | |
| 12 Mar 26 | Appointment of COO
strengthens operations, appointing Scott Lorimer as Chief Operating Officer |
+0.0% | |
| 03 Mar 26 | Appointment of CCO
strengthens commercial leadership, promoting Christine Wolosin to Chief Commercial Officer |
−6.9% | |
| 16 Feb 26 | Director dealing | Director/PDMR Shareholding | |
| 11 Feb 26 | Director dealing | Director/PDMR Shareholding | |
| 10 Feb 26 | Leadership Changes
– 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA products |
+5.4% | |
| 27 Oct 25 | Synthetic opDNA® utilised in Phase I/II US clinical trials
Synthetic opDNA® utilised in Phase I/II US clinical trials |
+8.3% | |
| 10 Oct 25 | Result of General Meeting
Cambridge, UK, 10 October 2025 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform announces that all of the resolutions prop |
−1.9% |
Company filings. Not investment advice.